Salidroside-Based Nanomedicines for Triple-Negative Breast Cancer: From Molecular Mechanisms to Clinical Translation
Breast Cancer: Targets and Therapy · 2026-06 · Volume 18 · 1-14
DOI: 10.2147/bctt.s605051 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Breast Cancer: Targets and Therapy, 2026-06. Verfasst von Xiaoying Ma und 5 weiteren Autor:innen. Beteiligte Einrichtung: School of Medicine, Qinghai University, Xining, Qinghai, 810001, People's Republic of China. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 3.0).
Abstract (Originalsprache)
Triple-negative breast cancer (TNBC) presents a substantial therapeutic challenge due to its aggressive biological characteristics and the absence of actionable molecular targets. Salidroside, the principal bioactive compound of Rhodiola rosea , demonstrates significant anticancer potential; however, its clinical application is severely constrained by poor bioavailability (less than 12%) and a short half-life (2.3 hours). This review contributes to the field in three key ways. Firstly, it systematically elucidates the molecular mechanisms of salidroside in TNBC, emphasizing its distinctive dual role in redox homeostasis: inducing ferroptosis in cancer cells while safeguarding normal tissues. Secondly, it critically assesses advanced nanomedicine strategies such as PLGA-PEG nanoparticles, lipid-polymer hybrid nanoparticles, and biomimetic RBC membrane-camouflaged carriers-designed to address pharmacokinetic limitations. Thirdly, and most importantly, it proposes a biomarker-driven framework, centered on BRCA1 methylation and HIF-1α, along with a three-phase translational roadmap to advance salidroside into a precision nanomedicine for TNBC. The diagram illustrates the process of using salidroside for treating triple-negative breast cancer. Initially, salidroside targets the cancer, but faces clinical limitations such as low bioavailability, short half-life and no standardized formulation. A solution is proposed using salidroside nanoparticles to target tumors with precision. This involves a multi-molecular pathway with HIF-1α and macrophages to minimize toxicity while augmenting efficacy. The ultimate goal is reaching clinical application.A diagram illustrating the clinical limitations of free salidroside and the proposed nanoparticle-based strategy for addressing triple-negative breast cancer. Keywords: salidroside, triple-negative breast cancer, nanomedicines, tumor immune microenvironment, ferroptosis
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- School of Medicine, Qinghai University, Xining, Qinghai, 810001, People's Republic of China.
- Department of Breast and Thyroid, Qinghai Provincial People's Hospital, Xining, Qinghai, 810001, People's Republic of China.
- Qinghai Clinical Research Center for High Altitude Diseases, Xining, Qinghai, 810001, People's Republic of China.
- Department of Medical Oncology, Qinghai Provincial People's Hospital, Xining, Qinghai, 810001, People's Republic of China.
ORCID-Profile: Xiaoying Ma
Zitieren
APA
Ma, X., Dang, S., Wang, H., Xia, L., Ma, P., & Qi, Y. (2026). Salidroside-Based Nanomedicines for Triple-Negative Breast Cancer: From Molecular Mechanisms to Clinical Translation. Breast Cancer: Targets and Therapy, Volume 18, 1-14. https://doi.org/10.2147/bctt.s605051
Vancouver
Ma X, Dang S, Wang H, Xia L, Ma P, Qi Y. Salidroside-Based Nanomedicines for Triple-Negative Breast Cancer: From Molecular Mechanisms to Clinical Translation. Breast Cancer: Targets and Therapy. 2026;Volume 18:1-14. doi:10.2147/bctt.s605051
BibTeX
@article{Ma2026,
author = {Ma, Xiaoying and Dang, Shengyan and Wang, Hui and Xia, Lei and Ma, Ping and Qi, Yujuan},
title = {Salidroside-Based Nanomedicines for Triple-Negative Breast Cancer: From Molecular Mechanisms to Clinical Translation},
journal = {Breast Cancer: Targets and Therapy},
year = {2026},
volume = {Volume 18},
pages = {1--14},
doi = {10.2147/bctt.s605051}
}
EUVIMED